Summary. Mycoplasma fermentans strains reputedly from human infections or tissue culture cells were much more susceptible to azithromycin than to clarithromycin or erythromycin. Lincomycin, clindamycin and several tetracyclines also exhibited good mycoplasmastatic activity but mycoplasmacidal concentrations were substantially greater than the MICs. Ciprofloxacin was the most active of three fluoroquinolones tested and was mycoplasmacidal at concentrations close to the MIC. Tiamulin and mupirocin were also very active. Synergy with specific M . fermentans antiserum plus guinea-pig complement was not observed with any class of antibiotic although the number of viable mycoplasmas was markedly reduced by the combined immunological components. Marked differences in susceptibility to various aminoglycosides were observed. Human strains isolated in cell-free media up to 1967 were aminoglycoside susceptible (MIC range 0.5-25 mg/L) but recent human isolates and strains isolated from tissue culture cells often showed either single or multiple aminoglycoside resistance (MIC > 500 mg/L). Two aminoglycoside-susceptible strains developed resistance to streptomycin or neomycin (> 500 mg/L) within five passages in broth containing streptomycin or neomycin, respectively. Resistance to tobramycin, kanamycin or gentamicin emerged after seven, eight and 14 cycles of exposure to the respective antibiotic. Streptomycin resistance was associated with a five-fold increase in resistance to tobramycin. Neomycin-, kanamycin-, gentamicin-and tobramycin-resistant variants showed mutual cross-resistance but remained susceptible to streptomycin. Induced resistance persisted for at least 17 passages in aminoglycoside-free broth. The use of aminoglycosides in human medicine and the frequent inclusion of some of these drugs in tissue cell cultures to combat bacterial and mycoplasmal contamination might account for the aminoglycoside resistance of recent M . ferment ans isolates.
Introduction
Mycoplasma fermentans was first isolated in 19501 from the genital mucosa of human patients with ulcerative balanitis. These strains were named " G " strains and were found to cause arthritis experimentally in mice. Subsequently M . fermentans was isolated from the bone marrows of leukaemic patients2 and from the joints of patients with rheumatoid arthriti~.~ These strains caused a leukaemia-like disease and death2. and recurrent mild arthritis5, respectively, in mice but their role in human disease is unresolved. Further attempts to isolate M . fermentarts from rheumatoid patients have generally been unsuccessfu16-9 and its role in rheumatoid arthritis remains unproven.
Since M . fermentans is also culture cellslO and may be a contaminant of tissue refractory to antibiotic treatment, great caution is needed before assigning a pathogenic role to this mycoplasma when cell cultures have been used during the isolation process.
The incognitus strain of M . fermentarts was isolated from NIH/3T3 cells during transfection studies with DNA extracted from Kaposi's sarcoma tissue from a patient with AIDS.ll The culture was shown subsequently to be lethal for silvered leaf monkeys. 12 The organism has been demonstrated in the tissues of non-AIDS patients with a lethal "flu-like" illness;13 it has also been isolated from the respiratory tracts of non-AIDS patients with acute respiratory disease14 and from children with community-acquired pneumonia. l5 Use of the polymerase chain reaction has indicated a much higher prevalence of M . fermentans in human immunodeficiency virus 1 (HIV-1) seropositive and seronegative patients than had been supposed previously. 16 M . ferrnentans (incognitus) enhances the cytotoxic effect of HIV-1 on CD,+ lymphocytes in culture1' and this can be reduced significantly by nontoxic doses of various tetracyclines," suggesting a possible co-factor role for M . ferrnentans in the pathogenesis of AIDS.
Information on the antibiotic susceptibility of M . ferrnentans strains is limited.l4. [19] [20] [21] [22] In the present study the susceptibility to various antimycoplasma drugs of strains of M . ferrnentans isolated over many years was investigated. The possibility of synergy between certain antibiotics and specific M . ferrnentans antibodies in the presence of guinea-pig complement and the development of resistance to aminoglycosides in vitro was also studied. 
Materials and methods

M . ferrnentans strains
Mycoplasrna media (rnodijied HayJEick'~)~~
Mycoplasma broth medium2, consisted of sterile Heart Infusion Broth (Difco) 90 ml, heat inactivated (1 h at 56°C) horse serum (Tissue Culture Services Ltd) 20 ml, fresh yeast extract 10 ml, 10 YO aqueous glucose 10 ml; phenol red and ampicillin were added to give final concentrations of 0.004 YO and 2.5 mg/ml, respectively. The medium was adjusted to pH 7.8 with sterile IN NaOH. Solid mycoplasma medium was prepared by adding 1.4 g of purified agar (Oxoid) to 90 ml of heart infusion broth before autoclaving (15 lb/15 min). The remainder of the broth components were added after cooling. Thallium acetate 0.025% was added to the agar medium to combat bacterial and mould contamination.
Preparation of M . ferrnentans stock cultures
M . fermentans strains were grown aerobically in modified Hayflick's broth. Cultures were incubated at 36°C until an acid colour shift to c. pH 6.8 occurred, and were then frozen at -70°C in 2 ml portions. Viable counts were done on thawed samples of each M . fermentans strain and identities were checked by the growth inhibition test25 with specific M . fermentans PG-18 antiserum. The bacterial purity of each culture was determined by plating on mycoplasma agar without inhibitors and incubating the plates aerobically and anaerobically at 36°C for at least 4 days.
Sources and preparation of antimicrobial agents
With the exception of clarithromycin, (Klaricid, Abbot t), azit hromycin (Zit hromax, Pfizer), ofloxacin (Tarivid, Hoechst), tiamulin hydrogen fumarate (Sandoz), chloramphenicol (Aldrich) and mupirocin (SmithKline Beecham), all other antimicrobial drugs were obtained from the Sigma Chemical Company. Most of the drugs were dissolved in de-ionised water to achieve a concentration of 1 mg/ml and sterilised by membrane filtration (0.22 pm pore size). Erythromycin, clarithromycin and azithromycin were dissolved or suspended in aqueous ethanol 10 YO v/v. The fluoroquinolones apart from ciprofloxacin hydrochloride, which is water soluble, were first dissolved in sterile 0.1 N NaOH and were then made up to volume with de-ionised water before sterilisation. Further drug dilutions were prepared at four times the required concentration in modified Hayflick's broth to allow for further dilution by other test components in the MIC tests.
Immunological reagents
M . ferrnentans PG-18 antiserum, raised in rabbits, was kindly supplied by Dr G. D. Windsor (Mycoplasma Experience Ltd). This antiserum showed specific activity against M . ferrnentans in the growth inhibition test with a 3-mm zone of inhibition against the homologous strain (PG-18), and an antibody titre of 32 in the metabolic inhibition test26 after heat inactivation (30 min at 56°C). Normal rabbit serum (Sigma) was also heat inactivated before use. Lyophilised guinea-pig complement (ICN Biomedicals Inc.) was reconstituted according to the manufacturer's instructions. Dilutions of these reagents were prepared in Hayflick's broth for use in the minimal ANTIBIOTIC SUSCEPTIBILITY OF M . FERMENTANS 423 inhibitory and minimum mycoplasmacidal concentration (MIC and MMC) tests. In preliminary studies, the anti-mycoplasma titres against M . fermentans PG-18 in the metabolic inhibition test were : normal rabbit serum < 4; guinea-pig complement, [8] [9] [10] [11] [12] [13] [14] [15] [16] . The dilutions of M . fermentans PG-18 antiserum and guinea-pig complement that just allowed mycoplasmal growth when used in combination were determined in checkerboard tests and were found to be 1 in 128 and 1 in 64, respectively. These concentrations of antiserum and complement were used in antibiotic synergy studies.
MIC and MMC tests
MIC tests were performed in 96-well microtitration plates (Costar UK Ltd) by a modification of the broth dilution method.27 Antimicrobial agents were diluted in Hayflick's broth (pH 7.8) and 0.05 ml of each drug dilution was added to separate wells. After addition of 0.1 ml of Hayflick's broth, each well was inoculated with 0.05 ml of broth containing between lo3 and lo6 cfu/ml of the appropriate M . fermentans strain. A drug-free, growth control, a sterility control and an end-point (pH 6.8) control were included with each plate. Plates were sealed with adhesive tape and incubated aerobically at 36°C. Initial MICs were recorded when the colour of the growth control matched that of the end-point control, a 2 50% colour change denoting the MIC. Final MICs were recorded 7 days later and were the lowest drug concentration in which no colour change was seen. MMCs were determined at the time of recording the initial MICs, by transferring 2pl from each well to Hayflick's agar with a 96-pin hand replicator (Intek Services Ltd, Horley, Surrey) and incubating the plates either aerobically or in a C0,-enriched atmosphere (Gaspak, BBL) at 36°C. MMCs were defined as the lowest concentration to inhibit mycoplasmal growth completely as judged by microscopy after incubation for at least 4 days. Antibiotic susceptibility tests in the presence of a combination of specific M . fermentans PG-18 antiserum and guinea-pig complement diluted to achieve concentrations that were just subinhibitory to M . fermentans PG-18 (see above) were performed on certain classes of drug to detect possible synergy. In these tests, 0-05 ml of M . fermentans PG-18 antiserum diluted 1 in 32 in Hayflick's broth and 0.05 ml of guinea-pig serum (diluted 1 in 16) were substituted for the 0.1 ml of Hayflick's broth in the MIC tests to give final dilutions of 1 in 128 and 1 in 64, respectively. MMC tests in the presence of antiserum and complement were performed as described above for tests without these immune components.
Induction of aminoglycoside resistance in M . fermentans
Development of resistance and cross-resistance to aminoglycosides in M . fermentans strains PG-18 and KL4 (aminoglycoside-sensitive) were studied in vitro. Tubes containing 1 -ml volumes of streptomycin, kanamycin, gentamicin, neomycin or tobramycin in a range of concentrations covering their respective MICs were inoculated with 0.2 ml of freshly thawed (from -70°C) cultures diluted to contain c. lo4 cfu/ml and incubated at 36°C. A 0.2-ml volume of culture from the highest drug concentration showing an acid colour change was transferred to a fresh series of tubes of drugcontaining broth. Such transfers were repeated at 4-day intervals, after which MICs of aminoglycosides for mycoplasmas growing in the highest concentration of drug were compared with those of the parent cultures (PG-18 or KL4). The identities and purities of all resistant variants were checked by testing inhibition of growth by specific antiserum and by plating cultures on inhibitor-free mycoplasma agar.
The stability of the induced aminoglycoside resistance was determined in each case by repeated passage of the resistant variants in aminoglycosidefree broth.
Results
The The tetracyclines and lincosamides were predominantly mycoplasmastatic agents against M . fermentans, the cidal concentration being up to 100-fold or up to 40-fold higher, respectively, than the initial MICs. As expected, all strains of M . fermentans were resistant to ampicillin (MIC > 2500 mg/L).
Synergy was not observed between any class of antimicrobial agent and specific M . fermentans PG-18 antiserum plus guinea-pig complement, although the colour changes denoting the end-point of MIC tests containing these reagents was markedly retarded (table  11) . Subculture of these tests on mycoplasma agar at the time of recording the initial MICs showed this delay to be associated with large reductions in mycoplasmas (< 50 cfu/2-pl sample) from wells containing specific antiserum and complement compared with confluent mycoplasmal growth from the control wells.
Marked differences were observed in the susceptibility of M . fermentans strains to the aminoglycosides (table 111) . The G strains isolated in 1950 and rheumatoid strains (KL4 and KL8) isolated around 1967 in cell-free medium, were susceptible to all the aminoglycosides tested. The bone marrow strains (El0 and 262) which were isolated during the 1960s with the aid of cell cultures containing penicillin and streptomycin to suppress bacterial contamination were resistant to > 500 mg of streptomycin/L but susceptible to the other aminoglycosides. Strains GIM (joint isolate) and BRO (urethral isolate) isolated in 1992 without the use of cell cultures were also more resistant to streptomycin than to other aminoglycosides whereas M . fermentans incognitus and all of the cell-culture isolates were resistant to all the aminoglycosides. All strains were susceptible to the aminocyclitol, spectinomycin (initial MIC range 1-2.5 mg/L).
Resistance to streptomycin and neomycin (MIC > 500 mg/L) emerged within five passages in broth containing the appropriate aminoglycoside (table  IV) . Resistance to tobramycin (MIC > 500 mg/L) emerged after seven passages in tobramycin-containing broth and to kanamycin (MIC > 250 mg/L) after eight passages in kanamycincontaining broth. Resistance to gentamicin (MIC > 500 mg/L) was observed only after 14 passages in gentamicin-containing broth. Development of streptomycin resistance was associated with increased resistance to tobramycin but not to the other aminoglycosides tested. In contrast, variants resistant to neomycin, kanamycin, tobramycin or gentamicin were cross-resistant to these aminoglycosides but remained susceptible to streptomycin (table IV) . In all but one case, resistance persisted for at least 17 passages in aminoglycoside-free broth.
Discussion
There are relatively few reports of the antimicrobial susceptibilities of M . fermentans. In the most comprehensive study,14 the susceptibilities of 24 M . fermentans strains from various sources to 10 antimicrobial agents were compared. The results of the current study are broadly consistent with earlier results, despite differences in the MIC methods used in the different laboratories, and also provide new data on previously unreported compounds.
Most striking was the greater anti-M. fermentans activity of azithromycin than that of the related macrolides, erythromycin and clarithromycin. Since mycoplasmacidal concentrations of azithromycin are likely to be achieveable in human blood and tissues, this antibiotic should be considered for the treatment of systemic M . fermentans infections in man, particularly as it persists in serum, is concentrated within tissues and penetrates mammalian cells,28 which are all sites of M . fermentans infection.ll9 1 3 9 29 The importance of adequate blood and tissue levels of antibiotics was also stressed by Hayes et al.14 who concluded that drugs which satisfy those criteria and which are sufficiently active against M . fermentans for human use include ciprofloxacin, levofloxacin (not tested in the current study), clindamycin, lincomycin, doxycycline and tetracycline.
The fluoroquinolones, together with the veterinary antibiotic tiamulin and the topical antibiotic mupirocin, appear to be mycoplasmacidal at concentrations close to the MIC. Tiamulin is not licensed for human use and mupirocin is unstable in vi~o.~' However, these drugs and azithromycin might offer alternative means of eradicating M . fermentans from tissue culture cells. Ciprofloxacin has already been found to be effective in this respect. 31 Mycoplasma infections may be very difficult to eradicate from immunocompromised patients.32* 33 The persistance of M . pneumoniae in a patient with hypogammaglobulinaemia despite prolonged treatment with tetracycline, erythromycin and doxycycline has been It has been s u g g e~t e d~~,~~ that in hypogammaglobulinaemic patients infected with M . pneumoniae, antibiotic treatment should be supplemented with plasma obtained from immunocompetent patients known to have high circulating antibody. Elimination of Ureaplasma urealyticum has been achieved in an aggammaglobulinaemic patient with simultaneous antibiotic and hyperimmune goat antiserum (P. M. Furr, personal communication). Such cures could be due either to synergy between certain antibiotics and specific antibodies in the presence of serum complement or to reductions in the mycoplasma load sufficient for cellular immune mechanisms to cope with the infection. Since synergy was not found in the current study, but mycoplasma numbers were markedly reduced by the antiserum and guinea-pig complement, the second of these hypotheses seems more likely.
Marked resistance of some M . fermentans strains to certain aminoglycosides has been reported previo~sly.'~, 351n those studies, M . fermentans incognitus and other M . fermentans strains derived from urine sediments from AIDS patients were compared with isolates from an outbreak of acute respiratory infection in Canada, an isolate from a patient with leukaemia,2 various cell culture isolates and the type strain PG-18. Significant differences in the broth MICs of aminoglycosides for M . fermentans strains from different sources were not apparent. However, the present results show clearly that early M . fermentans isolates obtained in cell-free media were susceptible to all of the aminoglycosides tested, whereas strains isolated in cell cultures were highly resistant to streptomycin, an aminoglycoside commonly incorporated in tissue culture media to suppress bacterial contamination. The experiments also showed that M . fermentans strains obtained more recently without the use of cell cultures were also resistant to streptomycin, suggesting that resistance to streptomycin had been acquired through use of the drug. These strains and the earlier isolates were all susceptible to the deoxystreptamine group of aminoglycosides (neomycin, kanamycin, gentamicin, tobramycin). However, M . fermentans incognitus and all strains derived from cell cultures showed cross-resistance to all aminoglycosides tested. In the case of the cell culture strains, this may have been due to exposure to streptomycin and other aminoglycosides during attempts to remove bacterial or mycoplasmal contaminants from tissue culture cell stocks, as kanamycin, gentamicin and neomycin are often used for this purpose.1o The demonstration of aminoglycoside cross-resistance in M . fermentans incognitus throws doubt on the origin of this strain since it was detected originally during transfection studies with NIH/3T3 cells.
To ascertain the ease with which M . fermentans develops resistance to individual aminoglycosides and the cross-resistance patterns which arise following development of resistance to particular aminoglycosides, habituation experiments were performed in vitro. These tests showed that high resistance to the streptidine-containing aminoglycoside, streptomycin, developed within five passages in streptomycin-containing broth, and that such variants were not crossresist ant to deoxys t rep t amine-con taining aminoglycosides, other than tobramycin. Conversely, deoxystreptamine-containing aminoglycosides induced cross-resistance to other members of that group, but not to streptomycin. These induced resistances were generally stable, indicating that once resistance had developed it was permanent. The mechanisms by which aminoglycoside resistance developed were not studied.
These results indicate that aminoglycoside resistance in M . fermentans is associated with previous exposure to these antibiotics, but that exposure to streptomycin alone does not trigger multiple resistance. The use of streptomycin and other aminoglycosides in human medicine and the frequent inclusion of some of these drugs in cell cultures to combat bacterial and mycoplasmal contamination may account for the high single or multiple aminoglycoside resistances in recent M . fermentans isolates. The rapid development of multiple aminoglycoside resistance demonstrated in vitro indicates that such resistance could develop in patients treated with any aminoglycoside. Naturally susceptible M . fermentans strains could also develop multiple aminoglycoside resistance during the isolation process if tissue cultures
